Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

AstraZeneca

Regeneron Pharmaceuticals

Roche Holding AG

NASHVILLE, Tenn. & TARRYTOWN, N.Y. & WILMINGTON, Del. & BAGSVAERD, Denmark & BASEL, Switzerland--(BUSINESS WIRE)--Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ (“Changing Healthcare for People of African Ancestry through an InterNational Genomics & Equity”) initiative to create better health care and outcomes for all. The Together for CHANGE initiative seeks to addr.

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

DexCom

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Inspire Medical Systems Inc

Intuitive Surgical

Eli Lilly

Insulet

ResMed

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.

Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B

Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a blood pressure drug for with potential applications in cardiovascular and kidney disease, the Danish group said today. Buoyed by the success of its diabetic treatments Ozempic and Wegovy, which have also been shown to cut weight and reduce heart attack risk, Novo Nordisk has surged to become Europe's biggest company.

Novo Nordisk buys blood pressure treatment to bolster diabtetes portfolio

Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.

Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain

The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.

Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal

Novo Nordisk (NVO) agreed to buy ocedurenone, a drug that treats uncontrolled hypertension and has the potential to be used in cases of cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion.

Novo Nordisk Buys Hypertension Drug in $1.3 Billion Deal

Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.

Novo Nordisk in $1.3 bln deal to buy hypertension drug

Novo Nordisk A/S NVO, +1.96% NOVO.B, +0.08% said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease.

Novo Nordisk to buy hypertension treatment from for $1.3 billion from KBP Biosciences

Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.

Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences

Ozempic and Wegovy have soared in popularity because of their ability to help people lose weight. Some recent reports, however, have described several potential side effects of concern.

1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs

Novo Nordisk (NVO) boosted its guidance for the second time in two months as demand soars for its diabetes treatments, Ozempic and Wegovy. American depositary receipts (ADRs) of Novo Nordisk rose close to 2% to an all-time high on Friday following the news.

Novo Nordisk Boosts Its Guidance on Demand for Its Weight-Loss Drugs, Again

The Danish pharmaceutical developer updated its 2023 guidance. It raised its projected growth rates for both sales and operating profit.

Why Novo Nordisk Stock Raced Higher Today

Novo Nordisk now expects 2023 sales growth of between 32% and 38%.

Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy

Campbell Soup

General Mills

Hershey

Kellogg

Kraft Heinz

Mondelez

McCormick

Invesco Dynamic Food & Beverage ETF

J. M. Smucker

Simply Good Foods

Tyson Foods

Hostess Brands

Consumer Staples Select Sector SPDR Fund

Bernstein analysts set out to determine that, analyzing online data to better understand changes in eating habits — and to evaluate which food companies may be most affected. They published the results in a report Friday.

What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.

Novo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.

Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic

Novo Nordisk (NYSE:NVO)'s shares have jumped after it lifted annual guidance, predicting a boost from higher sales of its diabetes drug Ozempic in the US. Europe's most valuable company, after recently dethroning LVMH, said that for the third-quarter its sales jumped 38% year-on-year at constant currency, while Ebit rose 47%.

Novo Nordisk ups guidance, sees higher sales of Ozempic

Novo Nordisk NVO, +1.36% on Friday boosted its full-year 2023 profit and sales outlook, reflecting heightened expectations for Ozempic and Wegovy sales. The company now projects full-year sales growth of 32% to 38%, up from 27% to 33% previously, and operating profit growth of 40% to 46%, up from 31% to 37% previously.

Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy

Novo Nordisk has raised the outlook for its full-year sales and operating profit, the Danish drugmaker said in a statement on Friday.

Novo Nordisk raises outlook for full-year sales, operating profit

Bagsværd, Denmark, 13 October 2023 – Novo Nordisk today announced that the sales and operating profit growth at constant exchange rates (CER) for the first nine months of 2023 and that the full-year sales and operating profit outlook at CER have been raised.

Novo Nordisk raises sales and operating profit outlook for 2023

Hormel Foods

Coca-Cola

PepsiCo

1 Dividend Legend Potentially Set To Soar And 2 To Ignore

Conagra Brands

Walmart

But does Novo Nordisk's good fortune translate to lower sales for companies like Walmart Inc. NYSE: WMT, Coca-Cola Co. NYSE: KO and PepsiCo Inc. NASDAQ: PEP?

Will Higher Ozempic Use Mean Slimmed-Down Food Sales?

Novo Nordisk on Thursday warned of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online as illegal traders seek to take advantage of their huge popularity, putting users' health at risk.

Novo Nordisk warns online offers of fake Ozempic, Wegovy are on the rise

Boston Scientific

CareTrust REIT

Exact Sciences

Life Time Group Holdings

Topgolf Callaway Brands Corp

Royal Caribbean Cruises

There's no doubt that America is aging. The numbers do not lie.

7 Affordable Stocks to Invest in as America's Population Ages

Shares of biotechnology firm CSL fell to a four-year low on Thursday, after rival Novo Nordisk's Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients.

Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns

News for Novo Nordisk Stock (NVO)